在挪威成年人中使用质子抑制剂 - 全国药物使用研究
Reidar Fossmark1,2, Sveinung Molnes3, Liv Sagatun2,3
1Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.
Pharmacology research & perspectives
|October 1, 2025
概括
质子抑制剂 (PPI) 的使用在十年内激增2.46倍,主要是食道疾病和GERD处方. 这种PPI使用的增加,特别是在初级保健中,表明潜在的过度使用,需要进一步调查.
科学领域:
- 药理学和药理学流行病学
- 胃肠病学 胃肠病学
- 公共卫生 公共卫生
背景情况:
- 质子抑制剂 (PPI) 的使用在西方国家显著增加.
- 有关未经证实的指示和长期PPI影响存在担忧.
- 了解国家处方模式对于药物安全至关重要.
研究的目的:
- 分析2009年至2022年挪威PPI的流行,发病率,适应症和处方趋势.
- 确定PPI使用量增加背后的关键驱动因素.
- 评估PPI启动和上部内镜手术之间的关联.
主要方法:
- 使用挪威处方数据库和挪威患者登记数据 (2009-2022) 进行全国性药物使用研究.
- 计算流行,长期和偶发的PPI使用情况.
- 对PPI指示和上部内镜率的诊断代码的分析.
主要成果:
- 抗胰岛素预防剂的处方从43增加到106DDD/1000人/天,流行使用率从3.5%上升到9.9%.
- 主要指示包括食道疾病和GERD,用于肌肉骨疾病,疼痛和预防的使用增加.
- 发生PPI使用的上部内镜率从25.3%下降到11.1%.
结论:
- 普遍使用的PPI增加了2.46倍,主要是由于食道疾病,GERD和初级保健预防的处方.
- 这些发现表明PPI可能过度使用,突出了针对性策略的必要性.
- 需要进一步的研究来优化PPI的处方,并减轻潜在的长期风险.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
851
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
851
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Peptic Ulcer Disease IV: Management
436
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
436
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
944
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
944
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
197
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
197
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
639
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
639


